News and Trends 23 Nov 2022 BIA and Exopharm sign joint research agreement to develop integrated technology Slovenian-based Sartorius BIA Separations (BIA), a bio-chromatography company, and Australia’s Exopharm Ltd., a company working with transformative medicines using exosomes, or extracellular vesicles (EVs), have entered into a formal collaboration. A material transfer agreement has been signed by both companies and an associated collaborative program has been implemented which aims to exploit the synergy of […] November 23, 2022 - 4 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 21 Nov 2022 Agreement boosts mRNA manufacturing in Singapore RVAC Medicines Pte. Ltd., a messenger RNA (mRNA) technology platform company, and the Agency for Science, Technology and Research (A*STAR) have signed a research collaboration agreement to jointly study and develop solutions to build mRNA manufacturing and analytics capabilities in Singapore. RVAC and A*STAR will set up a joint laboratory based at A*STAR’s Bioprocessing Technology […] November 21, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 14 Nov 2022 Nutcracker Therapeutics sees anti-tumor responses of lead mRNA immunotherapy Nutcracker Therapeutics, Inc. has presented the first set of preclinical data for its lead oncology mRNA therapeutic, NTX-250, at the 37th annual Society for Immunotherapy of Cancer meeting. The company said the data demonstrate that NTX-250 has the ability to elicit strong anti-tumor responses in C3.43 murine tumor models and induce an immune response in […] November 14, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 10 Nov 2022 Novel branched lipid boosts mRNA delivery to cells A novel branched lipid that is highly stable in storage and is highly efficient in delivering mRNA to cells has been developed. Messenger RNA (mRNA) is a biological molecule that transfers the information coded by genes in the nucleus to the cytoplasm for protein synthesis by ribosomes. mRNA sequences can be designed to encode specific […] November 10, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 4 Oct 2022 Astellas and Pantherna to work together on mRNA-based medicine through direct reprogramming Astellas Pharma Inc. and Pantherna Therapeutics GmbH have entered into a new technology evaluation agreement for research to generate mRNA-based regenerative medicine programs using direct reprogramming (transdifferentiation). Direct reprogramming is the direct conversion of the fate of cells without passing through the pluripotent state. This agreement expands the scope of the technology evaluation agreement for […] October 4, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 3 Oct 2022 Canada injecting $11.1M into mRNA vaccine technology at University of British Columbia The Canadian government is providing more than C$11.1 million (US$8.1 million) for two new mRNA vaccine projects at the University of British Columbia (UBC). The funding, through the Pacific Economic Development Agency of Canada (PacifiCan), is for UBC to enhance the delivery and efficacy of mRNA vaccines. PacifiCan is investing the money through its Regional […] October 3, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 19 Sep 2022 Global consortium looks to develop breakthrough RNA-based anti-cancer immunotherapy The Hadassah Cancer Research Institute (HCRI) at the Hadassah University Medical Center in Jerusalem, Israel, is to lead CanceRNA, a global consortium aiming to apply RNA-based therapeutics to successfully unlock anti-cancer immune responses. While RNA-based therapies, namely mRNA vaccines, shone during the pandemic and saved millions of lives, they have yet to be successfully tested […] September 19, 2022 - 2 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 14 Sep 2022 Capstan Therapeutics launches with $165M to deliver on in vivo cell engineering Capstan Therapeutics, Inc. has launched today with $165 million in financing to combine cell therapy and genetic medicines to help bring safer, first-in-class medicines to more patients in multiple indications. Capstan Therapeutics’ foundational precision in vivo engineering technology builds on research conducted in the laboratories of mRNA and cell therapy scientists at the University of […] September 14, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 7 Sep 2022 Benchling launches solution to boost mRNA and RNA therapeutics development Benchling has launched what it says is the industry’s first full set of capabilities for designing, modeling, and studying natural and chemically modified RNA in a single solution. As the biopharma industry increases its focus on developing RNA therapeutics, Benchling said its new RNA solution is the first purpose-built offering on the market to help […] September 7, 2022 - 3 minutesmins - By Jim Cornall Share WhatsApp Twitter Linkedin Email
News and Trends 6 Sep 2022 Lonza and Touchlight collaboration will expands customer’s access to DNA Manufacturing partner, Lonza, has today (September 6) announced a collaboration with Touchlight, a biotech company that works with enzymatic DNA production enabling genetic medicine. Through this collaboration, Lonza says it will have the ability to expand it end-to-end offering for mRNA manufacturing with an additional source of DNA raw material. This material comes from Touchlight’s […] September 6, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 30 Aug 2022 Potential new cancer treatment target discovered by researchers in Sweden A previously unknown mechanism that can control tumor growth in cultured cells and mice has been identified by researchers at the University of Gothenburg, Sweden. This discovery may potentially enable future development of new drugs against a range of cancer diseases. In a research article published in the journal Nature Communications, the Gothenburg scientists described […] August 30, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email
News and Trends 29 Aug 2022 Strategic collaboration announced in China to accelerate the development of bacterial drugs A strategic cooperation between Porton Advanced Solutions and Suzhou Royaltech Med Co., Ltd was announced today (August 29). The companies say the collaboration which was agreed earlier in the month (August 19) is set to integrate the resources and capabilities of both parties. The say it will jointly promote the establishment of microbial vectors used […] August 29, 2022 - 2 minutesmins - By Liza Laws Share WhatsApp Twitter Linkedin Email